Type 1 Insulin-like Growth Factor Receptor Targeted Therapies in Pediatric Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2013 Feb 6

PMID 23383402

Citations 7

Authors

Michael J Wagner

Robert G Maki

Affiliations

Soon will be listed here.

Abstract

Data from over 20 years ago demonstrated potential use for insulin-like growth factor (IGF) signaling modulators, specifically with IGF-1R antagonists, in a variety of pediatric and adolescent cancers, particularly in sarcomas. However, in spite of promising preclinical data, IGF-1R inhibitors have not had the success as single agents that was originally hoped for in clinical trials. Several potential mechanisms exist by which tumors are resistant to IGF-1R inhibitors. Notably, these resistance mechanisms are currently best understood in Ewing sarcoma and alveolar rhabdomyosarcoma. Various treatment schema have been proposed as a potential way to overcome this resistance. The use of IGF-1R inhibitors, mechanisms of resistance, and current ongoing clinical studies using IGF-1R inhibitors in pediatric cancers are reviewed here.

Citing Articles

Insights into Personalized Care Strategies for Wilms Tumor: A Narrative Literature Review.

Karam S, Gebreil A, Alksas A, Balaha H, Khalil A, Ghazal M Biomedicines. 2024; 12(7).

PMID: 39062028 PMC: 11274555. DOI: 10.3390/biomedicines12071455.

Overall review of curative impact and barriers of CAR-T cells in osteosarcoma.

Li G, Wang H, Meftahpour V EXCLI J. 2024; 23:364-383.

PMID: 38655095 PMC: 11036068. DOI: 10.17179/excli2023-6760.

Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults.

Wagner M, Gopalakrishnan V, Ravi V, Livingston J, Conley A, Araujo D Oncologist. 2017; 22(10):1271-1277.

PMID: 28710342 PMC: 5634776. DOI: 10.1634/theoncologist.2016-0464.

Molecular profiling of childhood cancer: Biomarkers and novel therapies.

Saletta F, Wadham C, Ziegler D, Marshall G, Haber M, McCowage G BBA Clin. 2015; 1:59-77.

PMID: 26675306 PMC: 4633945. DOI: 10.1016/j.bbacli.2014.06.003.

IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas.

Huang X, Park H, Greene J, Pao J, Mulvey E, Zhou S PLoS One. 2015; 10(7):e0133152.

PMID: 26173023 PMC: 4501840. DOI: 10.1371/journal.pone.0133152.

References

Kolb E, Gorlick R, Houghton P, Morton C, Lock R, Carol H . Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008; 50(6):1190-7. DOI: 10.1002/pbc.21450. View

Demetri G, van Oosterom A, Garrett C, Blackstein M, Shah M, Verweij J . Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006; 368(9544):1329-38. DOI: 10.1016/S0140-6736(06)69446-4. View

Kolb E, Kamara D, Zhang W, Lin J, Hingorani P, Baker L . R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts. Pediatr Blood Cancer. 2010; 55(1):67-75. DOI: 10.1002/pbc.22479. View

Janeway K, Albritton K, Van Den Abbeele A, DAmato G, Pedrazzoli P, Siena S . Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatr Blood Cancer. 2009; 52(7):767-71. DOI: 10.1002/pbc.21909. View

Janeway K, Zhu M, Barretina J, Perez-Atayde A, Demetri G, Fletcher J . Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification. Int J Cancer. 2010; 127(11):2718-22. PMC: 2947557. DOI: 10.1002/ijc.25247. View

Paugh B, Qu C, Jones C, Liu Z, Adamowicz-Brice M, Zhang J . Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol. 2010; 28(18):3061-8. PMC: 2903336. DOI: 10.1200/JCO.2009.26.7252. View

van Golen C, Schwab T, Kim B, Soules M, Oh S, Fung K . Insulin-like growth factor-I receptor expression regulates neuroblastoma metastasis to bone. Cancer Res. 2006; 66(13):6570-8. DOI: 10.1158/0008-5472.CAN-05-1448. View

Petricoin 3rd E, Espina V, Araujo R, Midura B, Yeung C, Wan X . Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res. 2007; 67(7):3431-40. DOI: 10.1158/0008-5472.CAN-06-1344. View

Spillane A, AHern R, Judson I, Fisher C, Thomas J . Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. J Clin Oncol. 2000; 18(22):3794-803. DOI: 10.1200/JCO.2000.18.22.3794. View

10.

Scotlandi K, Benini S, Nanni P, Lollini P, Nicoletti G, Landuzzi L . Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Res. 1998; 58(18):4127-31. View

11.

Prieur A, Tirode F, Cohen P, Delattre O . EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol. 2004; 24(16):7275-83. PMC: 479730. DOI: 10.1128/MCB.24.16.7275-7283.2004. View

12.

Abraham J, Prajapati S, Nishijo K, Schaffer B, Taniguchi E, Kilcoyne A . Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma. Mol Cancer Ther. 2011; 10(4):697-707. PMC: 4109806. DOI: 10.1158/1535-7163.MCT-10-0695. View

13.

Agaram N, LaQuaglia M, Ustun B, Guo T, Wong G, Socci N . Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res. 2008; 14(10):3204-15. PMC: 3805121. DOI: 10.1158/1078-0432.CCR-07-1984. View

14.

Garofalo C, Mancarella C, Grilli A, Manara M, Astolfi A, Marino M . Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing's sarcoma. Mol Endocrinol. 2012; 26(9):1603-16. PMC: 5416976. DOI: 10.1210/me.2012-1142. View

15.

Janeway K, Liegl B, Harlow A, Le C, Perez-Atayde A, Kozakewich H . Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. Cancer Res. 2007; 67(19):9084-8. DOI: 10.1158/0008-5472.CAN-07-1938. View

16.

Tolcher A, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin C, Rodon J . Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol. 2009; 27(34):5800-7. DOI: 10.1200/JCO.2009.23.6745. View

17.

Wang Y, Han X, Qiu Y, Xiong J, Yu Y, Wang B . Increased expression of insulin-like growth factor-1 receptor is correlated with tumor metastasis and prognosis in patients with osteosarcoma. J Surg Oncol. 2011; 105(3):235-43. DOI: 10.1002/jso.22077. View

18.

Juergens H, Daw N, Geoerger B, Ferrari S, Villarroel M, Aerts I . Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol. 2011; 29(34):4534-40. PMC: 3236653. DOI: 10.1200/JCO.2010.33.0670. View

19.

Huang F, Hurlburt W, Greer A, Reeves K, Hillerman S, Chang H . Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model. Cancer Res. 2010; 70(18):7221-31. DOI: 10.1158/0008-5472.CAN-10-0391. View

20.

Wojtalla A, Salm F, Christiansen D, Cremona T, Cwiek P, Shalaby T . Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma. PLoS One. 2012; 7(10):e47109. PMC: 3466180. DOI: 10.1371/journal.pone.0047109. View